Integrated Molecular Characterization of Uterine Carcinosarcoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Cell

• Publication date

  2017-03-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2017.02.010PMID 28292439PMCID PMC5599133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The basics of epithelial–mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective

  2019cited by this paper
• Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

  2016cited by this paper
• A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

  2016cited by this paper
• Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

  2016cited by this paper
• Probing the Fifty Shades of EMT in Metastasis.

  2016cited by this paper
• Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

  2015cited by this paper
• In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas

  2015cited by this paper
• ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

  2015cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

  2014cited by this paper
• Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

  2014cited by this paper
• The emerging roles of ARID1A in tumor suppression

  2014cited by this paper
• A pan-cancer proteomic perspective on The Cancer Genome Atlas

  2014cited by this paper
• Epithelial-Mesenchymal Transition

  2014cited by this paper
• Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes

  2014influential reference
• WHO classification of tumours of female reproductive organs

  2014cited by this paper
• Oncogenic RIT1 mutations in lung adenocarcinoma

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

  2013cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• ARID1A mutations in cancer: another epigenetic tumor suppressor?

  2013cited by this paper
• Pan-cancer patterns of somatic copy-number alteration

  2013influential reference
• Integrated genomic characterization of endometrial carcinoma

  2013cited by this paper
• Use of mutation profiles to refine the classification of endometrial carcinomas

  2012cited by this paper
• An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

  2012influential reference
• Absolute quantification of somatic DNA alterations in human cancer

  2012influential reference
• Expression profiles of carcinosarcoma of the uterine corpus—are these similar to carcinoma or sarcoma?

  2012cited by this paper
• Chromodomain Helicase DNA-binding Protein 4 (CHD4) Regulates Homologous Recombination DNA Repair, and Its Deficiency Sensitizes Cells to Poly(ADP-ribose) Polymerase (PARP) Inhibitor Treatment*

  2012cited by this paper
• GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

  2011influential reference
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• The epithelial-mesenchymal transition (EMT) phenomenon.

  2010cited by this paper
• Pathologic and molecular features of uterine carcinosarcomas.

  2010cited by this paper
• A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers

  2010influential reference
• The basics of epithelial-mesenchymal transition.

  2009cited by this paper
• Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.

  2008cited by this paper
• A Clinical and Biological Comparison Between Malignant Mixed Müllerian Tumors and Grade 3 Endometrioid Endometrial Carcinomas

  2008cited by this paper
• Prognostic Features of Surgical Stage I Uterine Carcinosarcoma

  2007cited by this paper
• Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.

  2006cited by this paper
• Epithelial-mesenchymal transition

  2005cited by this paper
• Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

  2002cited by this paper
• Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus

  2000cited by this paper
• Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity.

  2000cited by this paper
• Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components.

  1998cited by this paper
• Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumours

  1997cited by this paper
• Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.

  1997cited by this paper
• Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis.

  1996cited by this paper
• International Agency for Research on Cancer.

  1968cited by this paper

• Clinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas with an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors.

  2026cites this paper
• Single‐nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification

  2026cites this paper
• Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma.

  2025cites this paper
• R-loops as a trigger for intra- and extrachromosomal DNA amplification in cancer

  2025cites this paper
• Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis

  2025cites this paper
• Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.

  2025cites this paper
• PTEN mutation status in uterine carcinosarcomas: A comprehensive overview and a new diagnostic approach.

  2025cites this paper
• Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression in endometrial carcinosarcoma

  2025cites this paper
• Efficient Network Automatic Relevance Determination

  2025cites this paper
• Multiomic analysis of CCNE1 amplification associated molecular and immune features in gynecological cancers

  2025cites this paper
• The RB protein: more than a sentry of cell cycle entry.

  2025cites this paper
• Ultrasound-assisted biosynthesis of gelatin-gold nanocomposite: investigation of its antioxidant activity and its performance as anti-endometrial cancer in vitro

  2025cites this paper
• The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers

  2025cites this paper
• Uterine carcinosarcoma with heterologous osseous elements: a case report of an extremely rare clinical occurrence with literature review

  2025cites this paper
• Epigenetic Signatures and Prognostic Biomarkers Analysis of Methylation-Driven Genes in Uterine Endometrial Carcinosarcoma.

  2025cites this paper
• Elucidating divergent biology in uterine carcinosarcoma

  2025influential citation
• A subset of serous tubal intraepithelial carcinoma (STIC)-like lesions and concurrent high-grade endometrial carcinoma are genomically related entities.

  2025cites this paper
• A rare case report of uterine carcinosarcoma with bilateral ovarian Brenner tumors

  2025cites this paper
• Clinicopathological Predictors of Recurrence in Uterine Sarcomas—A Narrative Review

  2025cites this paper
• The search for new therapeutic options for uterine carcinosarcoma.

  2025cites this paper
• Apoptosis-inducing factor (AIF) at the crossroad of cell survival and cell death: implications for cancer and mitochondrial diseases

  2025cites this paper
• Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterations

  2025cites this paper
• Prognostic significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in uterine carcinosarcoma

  2025cites this paper
• Comparative Molecular Profiling of "Mixed Endometrioid Adenocarcinoma and Adenosarcoma" of the Uterus and Ovary: A Multi-institutional Series of 14 Cases.

  2025cites this paper
• A Case of Endometrial Carcinosarcoma in a Breast Cancer Patient Treated with Tamoxifen and Literature Review

  2025cites this paper
• Impact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube

  2025cites this paper
• Molecular diversity in uterine carcinosarcoma: Beyond TP53.

  2025cites this paper
• Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR

  2025cites this paper
• Molecular subtypes and quantitative analysis of PD-L1 and tumor-associated immune cells in uterine carcinosarcoma

  2025cites this paper
• Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous Component

  2025cites this paper
• Heterochronic pelvic high-grade myxoinflammatory fibroblastic sarcoma and uterine endometroid carcinoma harboring common gene mutations: a rare case report with genomic analysis

  2025cites this paper
• Learning to estimate sample-specific transcriptional networks for 7,000 tumors

  2025cites this paper
• Genomics of uterine malignancies and the potential of precision medicine

  2025cites this paper
• Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes Recapitulates Molecular and Morphological Features of High-Risk Endometrial Cancer

  2025cites this paper
• CaMutQC: An R package for integrative quality control and filtration of cancer somatic mutations

  2025cites this paper
• Impact of TSC2 loss on progression-free survival in uterine carcinosarcoma: A retrospective analysis

  2025cites this paper
• Molecular findings in endometrial mucinous carcinoma of the gastric [Gastrointestinal] type: A report of 5 additional cases and a systematic review of the literature.

  2025cites this paper
• Tamoxifen induces PI3K activation in uterine cancer

  2025cites this paper
• Demographic features and prognostic factors of uterine carcinosarcoma: a study at a specialized center in Saudi Arabia

  2025cites this paper
• Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage.

  2025cites this paper
• Carcinosarcoma of the Endometrium—Pathology, Molecular Landscape and Novel Therapeutic Approaches

  2025influential citation
• Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma

  2025influential citation
• The ADCK Kinase Family: Key Regulators of Bioenergetics and Mitochondrial Function and Their Implications in Human Cancers

  2025cites this paper
• Surgical and Oncologic Outcomes in Uterine Carcinosarcoma: A Retrospective Cohort Analysis

  2025cites this paper
• Advances in endometrial cancer screening: a comprehensive review of current methods and emerging technologies

  2025cites this paper
• Collaborative framework on responsible AI in LLM-driven CDSS for precision oncology leveraging real-world patient data

  2025cites this paper
• Natural and induced epithelial-mesenchymal transition results in epigenetic silencing of HER2 overexpression

  2025cites this paper
• Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA

  2025cites this paper
• Detecting copy-number alterations from single-cell chromatin sequencing data by AtaCNA

  2025cites this paper
• TROP2 expression and therapeutic targeting in uterine carcinosarcoma.

  2025cites this paper
• Copy number variations in endometrial cancer: from biological significance to clinical utility

  2024cites this paper
• Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.

  2024cites this paper
• Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components

  2024influential citation
• Establishment and characterization of multiple patient-derived organoids from a case of advanced endometrial cancer

  2024cites this paper
• Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR

  2024cites this paper
• Intra-clustering analysis reveals tissue-specific mutational patterns

  2024cites this paper
• Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications

  2024cites this paper
• A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).

  2024cites this paper
• Loss of SMARCA4 induces sarcomatogenesis through epithelial–mesenchymal transition in ovarian carcinosarcoma

  2024cites this paper
• Dedifferentiated Endometrioid Cancer Is a Rare Morphological Variant of Uterus Cancer

  2024cites this paper
• Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics

  2024cites this paper
• Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.

  2024cites this paper
• Computational prediction of therapeutic response and cancer outcomes

  2024cites this paper
• Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids

  2024cites this paper
• Papillary and ductal patterns of mesonephric‐like adenocarcinomas are often overlooked: a retrospective revaluation of over 1000 endometrial carcinomas

  2024cites this paper
• The Diverse Aspects of Uterine Serous Cancer: An NCI workshop on the status of and opportunities for advancement of research.

  2024cites this paper
• Uterine carcinosarcoma: Unraveling the role of epithelial‐to‐mesenchymal transition in progression and therapeutic potential

  2024influential citation
• Ovarian carcinosarcoma of heterologous type occurring in an endometriotic cyst with 3-year recurrence-free survival: a case report and literature review

  2024cites this paper
• Malignant Mixed Mullerian Tumor (Carcinosarcoma) in the Female Genital Tract: A Retrospective Study From a Single Center in North India

  2024cites this paper
• RB Loss in p53 Abnormal Endometrial Carcinoma: Histological and Clinicopathological Correlates.

  2024cites this paper
• Functional impact of the hyperduplication genomophenotype in high copy number endometrial cancer

  2024cites this paper
• The three YTHDF paralogs and VIRMA are strong cross-histotype tumor driver candidates among m6A core genes

  2024cites this paper
• Translating biological insights into improved management of endometrial cancer

  2024cites this paper
• The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors

  2024cites this paper
• Uterine Carcinosarcoma: Outcome of Management of Eight Cases

  2024cites this paper
• Primary Peritoneal Carcinosarcoma in a Breast Cancer Patient Harboring a Germline BRCA2 Pathogenic Variant: Case Report

  2024cites this paper
• Supported Au NPs over magnetic chitosan-gelatin nanocomposite: Investigation of its catalytic activity for one-pot synthesis of tetrazoles, study of antioxidant activity and anti-uterine cancer performances

  2024cites this paper
• Alternative splicing of BAZ1A in colorectal cancer disrupts the DNA damage response and increases chemosensitization

  2024cites this paper
• Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma.

  2024cites this paper
• Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs

  2024cites this paper
• Prognostic Nomogram for Predicting Survival, Clinicopathological Analysis, and Racial Disparities in Uterine Carcinosarcoma: A Retrospective Population-Based Study

  2024cites this paper
• Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies.

  2024cites this paper
• Presentación polipoide de un carcinosarcoma primario de vagina. Un caso clinicopatológico de esta neoplasia excepcional

  2024cites this paper
• Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications

  2024cites this paper
• The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes

  2024cites this paper
• Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase.

  2024cites this paper
• Isolated left axillary nodal metastasis from endometrial carcinosarcoma: A case report and literature review

  2024cites this paper
• Case report: Characterization of the immunologic and molecular landscape in a unique presentation of invasive lobular carcinoma with concurrent uterine carcinosarcoma treated with immunotherapy

  2024cites this paper
• Uterine Carcinosarcoma (UCS): A Literature Review and Survival Analysis from a Retrospective Cohort Study

  2024cites this paper
• Immunohistochemical Investigation of P16 Expression in Curettage Biopsies

  2024cites this paper
• POLE-mutated Endometrial “Carcinosarcoma”

  2024cites this paper
• An Overview of Cancer Biology, Pathophysiological Development and It’s Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy

  2024cites this paper
• The three YTHDF paralogs and VIRMA are the major tumor drivers among the m6A core genes in a pan-cancer analysis

  2024cites this paper
• HPV-negative and high-grade finding in Pap cytology

  2024cites this paper
• OKN-007 is an Effective Anticancer Therapeutic Agent Targeting Inflammatory and Immune Metabolism Pathways in Endometrial Cancer.

  2024cites this paper
• Ovarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes

  2024cites this paper
• Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification

  2024cites this paper
• POLE-mutated uterine carcinosarcomas: a clinicopathologic and molecular study of 11 cases.

  2024cites this paper
• Carcinosarcom uterin – prezentare de caz

  2023cites this paper
• The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes

  2023cites this paper